Ascletis Announces Positive Topline Results from Phase III Study of Denifanstat (ASC40) for Acne Treatment

Hangzhou, China – Ascletis Pharma Inc., a clinical-stage biotechnology company focused on innovative therapies for metabolic and dermatologic diseases, has announced positive topline results from its Phase III open-label clinical study of Denifanstat (ASC40). This investigational drug is a first-in-class, once-daily oral fatty acid synthase (FASN) inhibitor being developed for the treatment of acne vulgaris.

The encouraging results mark a significant milestone for Ascletis and reinforce the company’s commitment to addressing unmet needs in acne management through novel mechanisms of action. Acne remains one of the most prevalent skin conditions worldwide, affecting adolescents and adults alike, and current therapies often present limitations related to efficacy, safety, and long-term use.

Overview of the Phase III Open-Label Study

The Phase III study was designed as an open-label clinical trial to evaluate the safety, tolerability, and efficacy of Denifanstat in patients with moderate to severe acne. The trial enrolled a broad population representative of real-world clinical practice, allowing researchers to assess how the drug performs under practical treatment conditions.

Participants received Denifanstat orally once daily over a defined treatment period. The primary endpoint focused on improvements in acne severity, while secondary endpoints included reductions in inflammatory and non-inflammatory lesion counts, overall skin appearance, and patient-reported outcomes.

Key Objectives of the Study

• To assess the clinical effectiveness of Denifanstat in reducing acne lesions
• To evaluate safety and tolerability with long-term daily oral use
• To support regulatory submissions for future commercialization

Positive Topline Results and Clinical Outcomes

The topline data demonstrated that Denifanstat achieved clinically meaningful improvements in acne severity. A significant proportion of patients experienced marked reductions in both inflammatory and non-inflammatory lesions, meeting or exceeding the predefined study endpoints.

Importantly, Denifanstat was generally well tolerated, with no unexpected safety signals reported. Most adverse events were mild to moderate in severity, and few participants discontinued treatment due to side effects. These findings are particularly notable given the chronic nature of acne and the need for therapies suitable for extended use.

Safety and Tolerability Profile

Safety assessments throughout the study showed a favorable profile for Denifanstat. Routine laboratory tests, vital signs, and clinical evaluations did not reveal any concerning trends. The absence of severe systemic side effects positions Denifanstat as a promising alternative to existing oral acne treatments, such as antibiotics or isotretinoin, which are often associated with significant risks.

Understanding Denifanstat and Its Mechanism of Action

Denifanstat (ASC40) is a selective inhibitor of fatty acid synthase (FASN), an enzyme that plays a central role in lipid synthesis. In acne pathogenesis, excessive sebum production driven by lipid synthesis contributes to clogged pores, bacterial growth, and inflammation.

By inhibiting FASN, Denifanstat reduces sebum production at its source, addressing one of the fundamental biological drivers of acne. This mechanism differentiates Denifanstat from traditional therapies that primarily target bacteria or inflammation rather than the underlying metabolic processes.

Why Targeting FASN Matters in Acne

Scientific research has increasingly highlighted the role of lipid metabolism in skin health. Overactive sebaceous glands produce excess sebum, creating an environment conducive to acne development. Targeting FASN offers a novel approach that may provide sustained benefits without the drawbacks of long-term antibiotic use or hormonal manipulation.

Implications for Acne Treatment Landscape

The positive Phase III results suggest that Denifanstat could become a game-changing oral therapy for acne patients who do not respond adequately to topical treatments or who cannot tolerate existing systemic options.

Acne treatment has long relied on a limited set of systemic drugs, many of which come with strict usage guidelines and safety concerns. Denifanstat’s once-daily oral dosing and favorable safety profile may improve patient adherence and quality of life.

Addressing Unmet Medical Needs

Many patients struggle with persistent or severe acne well into adulthood. Current systemic treatments are not always suitable for long-term use. Denifanstat’s novel mechanism and tolerability profile may help fill this gap, offering dermatologists a new tool to manage chronic acne more effectively.

Regulatory and Development Path Forward

Following the successful completion of this Phase III study, Ascletis plans to engage with regulatory authorities to discuss the next steps toward potential approval and commercialization. The company intends to compile comprehensive clinical data to support regulatory submissions in relevant markets.

Ascletis also continues to explore additional indications for Denifanstat, leveraging its FASN inhibition platform across metabolic and dermatologic diseases.

Company Perspective

According to company leadership, the positive topline results reinforce Ascletis’ strategic focus on innovative, first-in-class therapies. The company expressed confidence that Denifanstat could offer meaningful benefits to patients and healthcare providers alike.

Broader Impact on Dermatology Research

The success of Denifanstat underscores a broader trend in dermatology toward mechanism-based treatments. Rather than relying solely on symptomatic relief, new therapies aim to correct underlying biological pathways contributing to skin disease.

This approach aligns with advances in precision medicine and reflects a growing understanding of the complex interactions between metabolism, inflammation, and skin health.

About Ascletis Pharma

Ascletis Pharma Inc. is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies. With a strong pipeline spanning metabolic, liver, and dermatologic diseases, Ascletis aims to deliver transformative medicines that address significant unmet medical needs.

The company’s research capabilities and clinical development expertise position it as a key player in advancing next-generation therapies for chronic conditions.

Conclusion

The announcement of positive Phase III topline results for Denifanstat (ASC40) represents a major advancement in acne treatment research. As a first-in-class oral FASN inhibitor, Denifanstat offers a novel and potentially safer approach to managing acne, with the promise of improved outcomes for millions of patients worldwide.

With regulatory discussions on the horizon and further development underway, Denifanstat stands as a strong example of how innovative science can translate into meaningful clinical progress.

#Ascletis #Denifanstat #AcneTreatment #ClinicalTrial #SlimScan #GrowthStocks #CANSLIM